Soma Pharmacy Blognews

Drug Combo Brings Better Pain Relief (CME/CE)
For people with neuropathic pain, a combination of two commonly used drugs works better than either alone, researchers said.

Women’s Weight Tied to Healthy Aging
For women, the odds of being healthy at age 70 are best for those who don’t gain a lot of weight between ages 18 and 50 and who aren’t obese at 50, a new study shows.

Few Eating Enough Fruits, Veggies
Only 14% of U.S. adults and 9.5% of U.S. teens meet the government’s goals for eating enough fruits and vegetables, according to a new CDC report.

Estrogen May Improve Colon Cancer Survival
Younger women with advanced colon cancer live slightly longer than younger men with advanced disease, but the survival advantage disappears as women age and their estrogen levels drop, a new study shows.

High Heels Today, Foot Pain Tomorrow
A new study shows people who make poor shoe choices early in life by wearing unsupportive footwear like high heels, sandals, and slippers are much more likely to suffer from foot pain in later years.

Lupin Acquires US rights For Antara
For a cash consideration of $38.61m

Actavis Launches Topiramate In Four European Markets
Drug to be available in tablets of 25mg, 50mg, 100mg and 200mg

Pooled Clinical Data Analysis Shows ‘Januvia’ Lowers Blood Sugar Levels
Combination targets three key defects of diabetes

Renewed GMP certification for China Biologic Products’ Qianfeng subsidiary
China Biologic Products, Inc. (OTC Bulletin Board: CBPO) (“China Biologic,” or the “Company”), one of the leading plasma-based pharmaceutical companies in the People’s Republic of China (“PRC”), today announced that on September 2, 2009, the PRC’s State Food and Drug Administration (the “SFDA”) renewed SFDA certification of [...]

Slovenia’s pharmaceuticals and healthcare industry report from Research and Markets
Research and Markets (http://www.researchandmarkets.com/research/ff3d70/slovenia_pharmaceu) has announced the addition of the “Slovenia Pharmaceuticals and Healthcare Report Q4 2009″ report to their offering.